Theme03:Neurodegenerative disease

We are eager to develop innovative drugs as quickly as possible to bring relief to patients suffering from neurodegenerative diseases around the world!

We wish to collaborate with many partners bringing creative ideas and technologies.

Pharmaceuticals Research Center
Laboratory for Pharmacology

Creating for Tomorrow


“ Neurodegenerative disease ”

Recruitment theme 

Neurodegenerative disease

3-1 Novel drug target molecules, candidates, and therapeutic concepts in neurodegenerative diseases

Target disease 1: Multiple system atrophy (MSA)

Research interests:

  • Prevention and/or elimination of α-synuclein aggregation

Untargeted research:

  • Research for which there is no clear strategy to differentiate the product from its competitors
  • Symptomatic treatment concepts

Other conditions:

  • In vitro experimental results demonstrating the targeting mechanism of action (MOA) are required.

Target disease 2. Progressive supranuclear palsy (PSP)

Research interests:

  • Prevention and/or elimination of tau aggregation

Untargeted research:

  • Research for which there is no clear strategy to differentiate the product from its predecessor
  • Symptomatic treatment concepts

Other conditions:

  • In vitro experimental results demonstrating the targeting MOA are required.

Target disease 3. Solitary amyotrophic lateral sclerosis (sporadic ALS)

Research interests:

  • Prevention and/or elimination of TDP-43 aggregation and mislocalization

Untargeted research:

  • Research for which there is no clear strategy to differentiate the product from its predecessor
  • Symptomatic treatment concepts

Other conditions:

  • In vitro experimental results demonstrating the targeting MOA are required.

Target disease 4. Polyglutamine disease

Research interests:

  • Prevention and/or elimination of polyglutamine protein aggregation

Untargeted research:

  • Research for which there is no clear strategy to differentiate the product from its predecessor
  • Symptomatic treatment concepts

Other conditions:

  • In vitro experimental results demonstrating the targeting MOA are required.
3-2 Research tools and drug discovery technologies in the field of neurodegenerative diseases

1. Animal model that can evaluate drug efficacy in multiple system atrophy (MSA)

Research interests:

  • Data suggestive of motor dysfunction have already been obtained.

Untargeted research:

  • Animal models for conditions that do not involve α-synuclein.

2. Assay system using human induced pluripotent stem cells (iPSCs) for the evaluation of drug efficacy in neurodegenerative diseases

Research interests:

  • iPSCs for evaluating drug efficacy for tauopathy, solitary ALS, and polyglutamine disease
  • Cell assay system using patient-derived cells that show aggregation of α-synuclein, tau, TDP-43, or PolyQ proteins

Subscription 

Click “Apply” to proceed to the application form.

pagetopボタン